<DOC>
	<DOCNO>NCT02286817</DOCNO>
	<brief_summary>This trial Phase 1 study adolescent ADHD genetic disruption impact gene metabotropic glutamate receptor ( mGluR ) network . The objective study evaluate safety , tolerability , pharmacokinetics follow single-dose , oral administration NFC-1 evaluate safety tolerability obtain evidence effect NFC-1 ADHD severity global functioning follow four week continuous treatment . Exploratory analysis perform assess effect size specific mGluR-network gene ADHD base responsiveness patient NFC-1 . This study conduct single clinical site , Jefferson University Hospital PKU ( Philadelphia , PA ) .</brief_summary>
	<brief_title>Phase I Single Dose , Open-Label Pharmacokinetic Study Single-Blind , Placebo-Controlled Dose Escalation Study NFC-1 Adolescents With Attention-Deficit Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Patient 's weight within 5th 95th percentile age 2 . Patient ADHD define Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM5 ) Vanderbilt ADHD Rating Scale score ( Parent Teacher ) &gt; 16 baseline without conventional ADHD therapy 3 . Patient genotyped ( CAP/CLIA certify ) determine whether disruptive mutation gene within mGluRnetwork 4 . Patient nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month 5 . Patient judge good health , ADHD , base medical history , physical examination , vital sign measurement , laboratory safety test perform screen visit and/or prior administration study drug 6 . Female patient reproductive potential negative urine βhCG test screen prior drug administration . If sexually active , female participant agrees use ( and/or partner use ) two acceptable method birth control begin least 2 week prior administration study drug throughout study . Acceptable method birth control abstinence , 2 following : intrauterine device ( IUD ) , diaphragm , spermicide , cervical cap , contraceptive sponge , condoms 7 . Patient clinically significant abnormality electrocardiogram ( ECG ) perform screen visit and/or prior administration study drug 8 . Parent/legal guardian patient understand study procedure agree patient 's participation study indicate parental/legal guardian signature patient consent form patient signature assent form 1 . Patient parent/legal guardian , opinion investigator , mentally legally incapacitate , significant emotional problem time screen visit conduct study . Subjects prior diagnosis comorbid major psychiatric disorder ( i.e . aside ADHD ) , include major depression , bipolar disease , Tourette syndrome , schizophrenia , autism spectrum disorder pervasive development disorder , severe anxiety disorder 2 . Patient history illness , opinion study investigator , might confound result study pose additional risk patient participation study 3 . Patient history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease . Patients history uncomplicated kidney stone may enrol study discretion investigator 4 . Patient history stroke , chronic seizure , major neurological disorder 5 . Patient pregnant nursing mother 6 . Patient history extreme psychological aversion blood draws opinion investigator parent would result compromise study conduct . Patient history extreme physiologic difficulty venous access opinion investigator parent would result compromise study conduct 7 . Patient history inability swallow whole unadulterated pill , opinion investigator parent would result compromise study conduct 8 . Patient systolic diastolic blood pressure ≥ 95th percentile his/her age 9 . Patient consumes alcoholic beverage 10 . Patient consumes excessive amount caffeine , define great 4 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day 11 . Patient history significant multiple and/or severe allergy , anaphylactic reaction significant intolerability prescription nonprescription drug food 12 . Patient currently regular user ( include `` recreational use '' ) illicit drug ( include marijuana ) history drug ( include alcohol ) abuse within approximately 3 year 13 . Patient surgery , lose 5cc/kg blood , participate another investigational drug trial within 4 week prior screen visit . 14 . Laboratory abnormality indicate clinically significant hematologic , hepatobiliary , renal disease 1 . AST/SGOT &gt; 2.0 time upper limit normal 2 . ALT/SGPT &gt; 2.0 time upper limit normal 3 . Total bilirubin &gt; 2.0 time upper limit normal 4 . Hemoglobin &lt; 9 gm/dL 5 . White blood cell count &lt; 1,000/ mm3 6 . Platelet count &lt; 100,000/mm3 15 . Any investigational drug use within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>